
    
      ALBAN study will randomize 516 patients in 30 centers in France, according to a ratio 1:1 in
      the following arms of treatment:

        -  Arm A (control arm): BCG only

        -  Arm B (experimental arm): BCG+ atezolizumab

      The are two factors of stratifications (center and CIS).
    
  